Fujisawa Pharmaceutical Co., Ltd., has executed a collaborative research agreement with Pharmagenesis, Inc., with regard to triptolide derivatives, novel and potent immunosuppressants created by Pharmagenesis.
The agreement also gives Fujisawa an option to acquire the exclusive and worldwide (certain territories are under negotiation) development and marketing rights to Pharmagenesis’ compounds in the therapeutic areas of transplantation, autoimmune diseases and dermatology.
Upon the execution of the agreement, Fujisawa will start studies to evaluate likely clinical efficacy of the derivatives based on which the Company will decide to exercise the option.
Pharmagenesis develops anticancer therapies and treatments for cancer therapy-related bone-marrow suppression and for the management of transplant rejection.
The privately held company focuses on developing ethical pharmaceuticals from purified extracts of plants that have been employed in traditional Chinese medicine for more than 4,000 years.
Fujisawa Pharmaceutical is one of the leading pharmaceutical manufacturers in Japan.